PDUFA dates December 2019: FDA calendar and catalysts.
0 PDUFA dates fell in December 2019. The FDA calendar also recorded 7 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in December 2019
No PDUFA dates are disclosed for this period as of November 16, 2026.
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
December 2019: other FDA decisions and filings
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| December 6, 2019 | Avsola (infliximab-axxq) | AMGN | FDA approval | — | Approved | openFDA Drugs@FDA |
| December 13, 2019 | Nouress (cysteine hydrochloride) | BAX | FDA approval | — | Approved | openFDA Drugs@FDA |
| December 17, 2019 | Entyvio® (vedolizumab) | TAK | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| December 19, 2019 | Vocabria (cabotegravir sodium) | GSK | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| December 19, 2019 | Cabenuva Kit (cabotegravir; rilpivirine) | GSK | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| December 20, 2019 | Caplyta (lumateperone tosylate) | JNJ | FDA approval | — | Approved | openFDA Drugs@FDA |
| December 23, 2019 | Ubrelvy (ubrogepant) | ABBV | FDA approval | — | Approved | openFDA Drugs@FDA |
December 2019: dated readouts
No events in this view.
Questions
What PDUFA dates are in December 2019?
0 PDUFA dates fell in December 2019. The FDA calendar also recorded 7 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.